1
|
Wang Y, Zuo J, Hao W, Wu L, Liu F, Wang Q, He L, Peng P, Zhou Y, Li M, Yang Q, Wang X, Liu T, Potenza MN. Relationships Between Impulsivity, Methamphetamine use Disorder and Gambling Disorder. J Gambl Stud 2023; 39:1635-1650. [PMID: 36973505 DOI: 10.1007/s10899-023-10201-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/12/2023] [Indexed: 03/29/2023]
Abstract
Methamphetamine use disorder (MAUD) and gambling disorder (GD) frequently co-occur. Individuals with both conditions are typically more difficult to treat than those with either disorder alone. This study aimed to investigate the co-occurrence and clinical characteristics of people with MAUD and GD. Between March 2018 and August 2020, 350 men with methamphetamine use entering a compulsory drug rehabilitation center in Changsha, Hunan Province received semi-structured interviews. Participants completed the Barratt Impulsiveness Scale-11 and provided information on childhood upbringings and drug use characteristics. Independent sample t-tests compared differences between individuals with MAUD and with and without co-occurring GD. Dichotomous logistic regression was used to statistically predict co-occurring GD. The prevalence of GD was 45.1%. Most individuals (39.1% overall) had post-onset methamphetamine use (PoMAU-GD). The number of MAUD symptoms, history of gambling by family members, age of first sexual activity, and non-planning impulsivity statistically predicted PoMAU-GD, jointly explaining 24.0% of the total variance. The regression model fit well (HLχ2 = 5.503, p = 0.70), in which the specificity was 0.80, the sensitivity was 0.64, and the area under the curve was 0.79 (95%CI: 0.75-0.84). This study clarifies the prevalence of and potential risk factors for GD among individuals engaging in compulsory MAUD treatment in China. The high prevalence and associated clinical features of GD in the MAUD group highlight the importance of screening for GD in this population and intervening accordingly.
Collapse
Affiliation(s)
- Yingying Wang
- School of Physical Education and Health, Hunan University of Technology and Business, Changsha, China
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Jinsong Zuo
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
- School of Life Science and Chemistry, Hunan University of Technology, Zhuzhou, China
| | - Wei Hao
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Lingxiang Wu
- School of Science, Shaoyang University, Shaoyang, China
| | - Feng Liu
- Compulsory detoxification center of Changsha Public Security Bureau, Changsha, Hunan, China
| | - Qianjin Wang
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Li He
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Pu Peng
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Yanan Zhou
- Department of Psychiatry, Brain Hospital of Hunan Province (The Second People's Hospital of Hunan Province), Changsha, China
| | - Manyun Li
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Qian Yang
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Xin Wang
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China
| | - Tieqiao Liu
- Department of Psychiatry, The Second Xiangya, National Clinical Research Center for Mental Disorders, Hospital of Central South University, Changsha, China.
| | - Marc N Potenza
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
- Child Study Center, Yale University School of Medicine, New Haven, CT, USA.
- Connecticut Council on Problem Gambling, Wethersfield, CT, USA.
- Connecticut Mental Health Center, New Haven, CT, USA.
- Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA.
| |
Collapse
|
2
|
Ma YJ, Wang YY, Liu MQ, Fang T, Wei ZR, Chen SB, Tan H, Nunez YZ, Zhang XJ, Hao W, Malison RT, Kranzler HR, Gelernter J, Liu TQ, Yang BZ. Reliability and validity of DSM-IV and DSM-5 methamphetamine use disorder diagnoses using the Chinese Version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Drug Alcohol Depend 2021; 229:109047. [PMID: 34710713 DOI: 10.1016/j.drugalcdep.2021.109047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 09/02/2021] [Accepted: 09/04/2021] [Indexed: 01/02/2023]
Abstract
BACKGROUND The Semi-structured Assessment for Drug Dependence and Alcoholism (SSADDA) was developed to assess substance-use disorders and other psychiatric traits. We translated the SSADDA into Chinese and evaluated its inter-rater reliability and concurrent validity in diagnosing DSM-IV methamphetamine (MA) dependence and DSM-5 MA-use disorder (MUD). METHODS The sample comprised 231 participants who were interviewed using the Chinese SSADDA and the Mini-International Neuropsychiatric Interview (Chinese MINI) for concurrent validation. Of the 231 participants, 191 were interviewed by two different interviewers two weeks apart. We evaluated the inter-rater reliability and concurrent validity of the diagnoses using percent agreement and Cohen's kappa coefficient (κ). Cohen's linear weighted kappa was used to assess the reliability of DSM-5 MUD severity. RESULTS It showed good inter-rater reliability and no significant differences among the DSM-5 MUD (κ = 0.71), DSM-IV MA abuse or dependence (κ = 0.72), and the DSM-IV diagnoses of MA dependence (κ = 0.66) and abuse (κ = 0.68) tested separately. The weighted kappa was 0.67 across the three DSM-5 MUD severity levels. The reliability of each individual diagnostic criterion for DSM-5 MUD ranged from fair to excellent (κ = 0.41-0.80), except for "repeated attempts to quit/control use" (κ = 0.38). The concurrent validity based on MINI-derived diagnoses ranged from good to excellent (κ = 0.65-0.78). CONCLUSIONS This study shows that the Chinese version of SSADDA has good reliability and validity among Chinese MA users.
Collapse
Affiliation(s)
- Yue-Jiao Ma
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China; Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Ying-Ying Wang
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
| | - Meng-Qi Liu
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
| | - Ting Fang
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
| | - Zi-Rou Wei
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
| | - Shu-Bao Chen
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
| | - Haoye Tan
- Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Yaira Z Nunez
- Department of Psychiatry, Yale University School of Medicine, New Haven, and VA CT Healthcare Center, West Haven, CT, USA
| | - Xiao-Jie Zhang
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
| | - Wei Hao
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China
| | - Robert T Malison
- Department of Psychiatry, Yale University School of Medicine, New Haven, and Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, USA
| | - Henry R Kranzler
- Center for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine and VISN 4 MIRECC, Crescenz VAMC, Philadelphia, PA 19104, USA
| | - Joel Gelernter
- Department of Psychiatry, Yale University School of Medicine, New Haven, and VA CT Healthcare Center, West Haven, CT, USA; Departments of Genetics and Neuroscience, Yale University School of Medicine, USA
| | - Tie-Qiao Liu
- Department of Psychiatry, The China National Clinical Research Center for Mental Health Disorders, China National Technology Institute on mental disorders, Key Laboratory of Psychiatry and Mental Health of Hunan Province, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.
| | - Bao-Zhu Yang
- Department of Psychiatry, Yale University School of Medicine, New Haven, and VA CT Healthcare Center, West Haven, CT, USA.
| |
Collapse
|